INTRODUCTION
============

Chronic kidney disease (CKD) is a global health burden to patients and health care systems, with an estimated population prevalence of ∼10% \[[@sfz054-B1], [@sfz054-B2]\]. Treatment is supportive and aimed at preventing CKD progression. Key to achieving this goal is limiting further kidney injury \[[@sfz054-B3], [@sfz054-B4]\] by avoiding the use of nephrotoxic medications when alternative, safer therapies exist. Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most ubiquitously prescribed medications, and alternatives exist for many of their clinical applications \[[@sfz054-B5], [@sfz054-B6]\]. NSAIDs lead to decreased kidney perfusion via inhibition of prostaglandin synthesis \[[@sfz054-B7]\]. Their use in the general population is known to be strongly associated with the development of acute kidney injury, which in turn is a risk factor for CKD \[[@sfz054-B8], [@sfz054-B9]\].

International practice guidelines recommend complete NSAID avoidance in patients with a glomerular filtration rate (GFR) \<30 mL/min/1.73 m^2^ and avoidance of prolonged use in patients with a GFR \<60 mL/min/1.73 m^2^ \[[@sfz054-B4]\]. Despite these recommendations, there is evidence that many prescribers are unaware of the importance of NSAID avoidance in patients with impaired kidney function \[[@sfz054-B10]\]. As the primary care setting is the most frequent point of health care provider contact for many patients with CKD, it is important to better understand prescribing practices to patients with CKD in this setting. We therefore performed a systematic review to evaluate prescribing practices and the use of NSAIDs in adults with CKD. Our objective was to quantify and describe primary care NSAID prescribing practices and use among patients with CKD to elucidate the need for knowledge translation interventions aimed at reducing NSAID exposure in this vulnerable population.

MATERIALS AND METHODS
=====================

The protocol for this systematic review has been published on PROSPERO (registration number CRD42018081292). The review is reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.

Search strategy
---------------

We systematically searched MEDLINE and Embase (via Ovid) from inception to 17 October 2017 to identify observational studies examining NSAID prescribing practices or usage in CKD patients in a primary care setting. The full search strategy is reported in the [online appendix](#sup1){ref-type="supplementary-material"} ([Supplementary data](#sup1){ref-type="supplementary-material"}, Items SA1--SA2 and Tables SA1--SA2). We applied keywords for the concepts of 'kidney disease', 'non-steroidal anti-inflammatory' and 'prescription' and relevant database-specific Medical Subject Heading (MEDLINE) and EMTREE (Embase) terms. An exhaustive list of generic NSAID names was also included. Trade names were not included, as they were deemed unlikely to substantially increase the search sensitivity \[[@sfz054-B13]\]. To limit our search to the primary care setting, we combined two validated primary care/family practice search filters with a Boolean 'OR' operator to maximize sensitivity \[[@sfz054-B14], [@sfz054-B15]\]. We restricted our search to non-animal studies and conducted it without language restrictions. We queried authors of relevant studies regarding knowledge of ongoing or unpublished research in the area. We also manually searched the reference lists of relevant reviews and articles to identify additional studies.

Study selection
---------------

Two reviewers (C.L. and J.H.) independently screened titles and abstracts of identified studies. Studies deemed potentially relevant by either reviewer were read in full. Decisions to include or exclude full-text articles were made independently and disagreements were resolved through consensus. We included studies reporting NSAID use and/or prescription prevalence in CKD patients in primary care. For studies within multiple health care settings, \>50% of patients had to be included from the primary care setting and extraction of primary care data had to be feasible. We excluded studies describing only hospitalized patients. We restricted inclusion to studies whose objectives included describing or quantifying medication use and those in which CKD diagnosis was objectively determined using diagnostic codes or laboratory testing (defined as per international guidelines) \[[@sfz054-B4]\]. We restricted inclusion to cohort, case--control and cross-sectional designs (excluding commentaries, editorials, letters to the editor, reviews, case reports and case series). Clinical trials were excluded with the rationale that prescribing practices and factors influencing them would significantly differ from routine primary care practices \[[@sfz054-B16], [@sfz054-B17]\]. In studies where multiple prevalences were reported from the same population, we included the first measure taken after CKD diagnosis. A single study could contribute more than one prevalence value if it described distinct CKD populations.

We excluded studies in which the timing of NSAID use/prescription in relation to CKD diagnosis could not be established and those in which NSAID use/prescription clearly preceded CKD diagnosis or was established at the same time as CKD diagnosis; prevalence measures from these studies do not likely reflect prescribing to patients with known CKD. Seven study authors were contacted to clarify the timing of NSAID use/prescription in relation to CKD diagnosis, five of whom confirmed that the timing did not meet our inclusion criteria \[[@sfz054-B18]\] and two of whom provided information allowing us to include their study.

Data extraction
---------------

Data extraction was performed independently by two authors (C.L. and J.H.) using a standardized, pilot-tested form. Disagreements were resolved through consensus. Extracted data included study design, country, study period, number of CKD patients, method of CKD diagnosis, NSAID definition and prevalence of NSAID use and/or prescription.

Quality assessment
------------------

Study quality was assessed using a modified version of the Agency for Healthcare Research and Quality's Methodological Evaluation of Observational Research (MORE) checklist \[[@sfz054-B23]\]. This checklist is specifically designed for observational studies examining the incidence and prevalence of chronic diseases \[[@sfz054-B24]\]. MORE provides a descriptive quality assessment of studies and assigns 'no flaw', 'minor flaw', 'major flaw' or 'poor reporting' descriptors to each criterion that we adapted to signify a low, moderate, high or unclear risk of bias (due to poor reporting). All studies were included in the systematic review, regardless of their quality.

The checklist was adapted to our specific research question. In assessing external validity, MORE assigns a major flaw when the sampling frame is health care based, as it may not capture prevalence rates in the general population \[[@sfz054-B23]\]. As the purpose of our study was to evaluate prescriptions by health care practitioners, we did not assign a major flaw to studies using such sampling methods. However, we did assign a minor flaw to studies that used claims data that restricted to insured patients. MORE also assigns flaws to studies based on absolute cut-offs for participant response rates and exclusions from analysis, whereas we also considered whether studies assessed differences between responders and non-responders and between included and excluded patients. For the assessment of internal validity, we specifically evaluated whether NSAID prevalence was assessed objectively, whether it relied on patient recall for \<6 months or patient recall for \>6 months, assigning no flaw, a minor flaw or a major flaw, respectively.

Statistical analysis
--------------------

Prevalences of use/prescription are presented along with 95% confidence intervals (CIs). Period prevalences over varying follow-up times were converted to a yearly prevalence to allow comparability of results, assuming that the NSAID prescription rate remained stable throughout each individual study's follow-up period. Data from included studies were synthesized qualitatively via systematic review rather than quantitatively via meta-analysis due to important clinical heterogeneity across studies. As there were only two studies comparing NSAID use in CKD patients to that in non-CKD patients, we did not present relative effect measures \[[@sfz054-B25], [@sfz054-B26]\].

RESULTS
=======

Our search generated 8055 potentially relevant publications ([Figure 1](#sfz054-F1){ref-type="fig"}). After removal of duplicates and title/abstract screening, 304 articles were retrieved for full-text review. Of these, 12 met our inclusion criteria, 2 of which were derived from a single publication \[[@sfz054-B27]\]. Two additional studies were identified through reference screening of included articles. A total of 14 studies from 13 separate publications were thus included in our review.

![Flow diagram of included observational studies of NSAID prescription prevalence in primary care CKD patients.](sfz054f1){#sfz054-F1}

Study and patient characteristics
---------------------------------

The 14 studies included 49 209 CKD patients ([Tables 1](#sfz054-T1){ref-type="table"} and [2](#sfz054-T2){ref-type="table"}). Study size varied from 8 \[[@sfz054-B28]\] to 27 668 CKD patients \[[@sfz054-B29]\]. There were eight cohort studies \[[@sfz054-B26], [@sfz054-B27], [@sfz054-B29]\], three cross-sectional studies \[[@sfz054-B25], [@sfz054-B28], [@sfz054-B34]\], two studies of quality improvement interventions \[[@sfz054-B35], [@sfz054-B36]\] and one prospective survey \[[@sfz054-B37]\]. One publication described two separate CKD populations, which were considered independently in our analysis \[[@sfz054-B27]\]. Two studies were performed within a single primary practice center \[[@sfz054-B27]\]. The remaining studies were conducted across two or more practices, four of which grouped data from \>100 practices using centralized electronic medical records databases \[[@sfz054-B21], [@sfz054-B26], [@sfz054-B29], [@sfz054-B30]\].

###### 

Characteristics of studies assessing point prevalence of NSAID use among patients with CKD

  Reference (location)                                                         Source population                                                                                                                                   Patients with CKD, *n* (% female)                  Age (years), mean (SD)            CKD definition (calculation equation)                      NSAID definition                                                                       Study period   Prevalence of NSAIDs, % (95% CI)
  ---------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------- -------------------------------------------- ---------------------------------------------------------- ------------------------------------------------------------------------------------- -------------- ----------------------------------
  Dorks *et al.* \[[@sfz054-B25]\] (Germany)                                   21 nursing homes (\>96% followed by primary care physician)                                                                                    436 (75)[^a^](#tblfn1){ref-type="table-fn"}   83 (11)[^a^](#tblfn1){ref-type="table-fn"}  Single eCCr \<60 (C--G)                                    NSAID prescription or OTC use in nursing home chart                                      2014--15               20 (17--25)
  Stage 3: 76%                                                                                                                                                                                                                                                                                                                                                                                                                                                                          
  Stages 4--5: 24%                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
  Fox *et al.* \[[@sfz054-B35]\] (USA)                                         Patients from a private primary care practice and DM and/or HTN patients from an urban primary care practice                                                    181 (NR)                                     NR (\>18)                   Single eGFR (NR)                                           NSAID use in EMR or paper chart review                                                      NR                   13 (8--18)
  Stages 3--5: 100%                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Koffeman *et al.* \[[@sfz054-B26]\] (The Netherlands)                        Patients presenting a musculoskeletal complaint at primary care practices participating in the Integrated Primary Care Information database    285 (54)[^a^](#tblfn1){ref-type="table-fn"}   47 (17)[^a^](#tblfn1){ref-type="table-fn"}  Single eGFR (NR)                                           NSAID prescription issued during musculoskeletal complaint episode from EMR              2000--10               19 (14--24)
  Stages 4--5: 100%                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  Lioté *et al.* \[[@sfz054-B37]\] (France)                                    Patients with gout or gout-related arthritis in a random sample of primary care and rheumatology practices (primary care data presented)       112 (13)[^a^](#tblfn1){ref-type="table-fn"}   63 (11)[^a^](#tblfn1){ref-type="table-fn"}  Single eCCr (C--G or measured using a 24-h urine sample)   NSAID prescription recorded on a case report form during baseline visit                  2008--09                10 (4--15)
  Stages 3--5: 100%                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
  McIntyre *et al*. \[[@sfz054-B34]\] (UK)                                     Thirty-two primary care practices participating in the Renal Risk in Derby study                                                                                1741 (60)                                     73 (10)                    Two eGFRs separated by at least 3 months (MDRD)            NSAID prescription or OTC use by questionnaire (validated with latest prescription)      2008--10                8 (7--10)
  Stage 3A: 77%                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Stage 3B: 23%                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  Weddle *et al.*[^b^](#tblfn2){ref-type="table-fn"} \[[@sfz054-B27]\] (USA)   Resident-based primary care clinic                                                                                                                               29 (NR)                                       72 (6)                    CKD diagnosis present in patient's EMR                     NSAID prescription in EMR                                                                2014--15                21 (6--35)
  Weddle *et al*.[^c^](#tblfn3){ref-type="table-fn"} \[[@sfz054-B27]\] (USA)   Resident-based primary care clinic                                                                                                                               32 (NR)                                       74 (7)                    CKD diagnosis present in patient's EMR                     NSAID prescription in EMR                                                                  2014                 13 (10--24)

Values are given for whole study population.

Prospective cohort.

Retrospective cohort.

SD, standard deviation; eCCr, estimated creatinine clearance; C--G, Cockcroft--Gault formula; OTC, over the counter; HTN, hypertension; NR, not reported; EMR, electronic medical record; MDRD, Modification of Diet in Renal Disease equation.

###### 

Characteristics of studies assessing period prevalence of NSAID use among patients with CKD

  Reference (location)                                                 Source population                                                                                                             Patients with CKD, *n* (% female)                    Age (years), mean (SD)            CKD definition (calculation equation)             NSAID definition                                           Study period   Prevalence of NSAIDs, % (95% CI)
  -------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------- ------------------------------------------------ -------------------------------------------- ------------------------------------------------- --------------------------------------------------------- -------------- ----------------------------------
  Allen *et al.* \[[@sfz054-B31]\] (USA)                               Multispecialty group practice of 15 ambulatory health centers in Massachusetts (only 10% followed by a nephrologist)                     11 774 (60)                                      73 (12)                    Two eGFRs separated by at least 3 months (MDRD)   NSAID prescription in the EMR                                2008--9                 10 (9--10)
  Stage 3: 97%                                                                                                                                                                                                                                                                                                                                                                                                         
  Stage 4: 3%                                                                                                                                                                                                                                                                                                                                                                                                          
  Arora *et al*. \[[@sfz054-B32]\] (USA)                               Claims data from major insurer (analysis restricted to patients not referred to a nephrologist)                                          15 177 (61)                                      72 (NR)                    Two eGFRs separated by at least 3 months (MDRD)   Insurance claim for NSAID prescription                       2007--13               24 (23--25)
  Stage 3: 97%                                                                                                                                                                                                                                                                                                                                                                                                         
  Stage 4: 3%                                                                                                                                                                                                                                                                                                                                                                                                          
  Stage 5: \<1%                                                                                                                                                                                                                                                                                                                                                                                                        
  Guthrie *et al.* \[[@sfz054-B29]\] (Scotland)                        315 primary care practices contributing to the Scottish program for improving clinical effectiveness in primary care    27 668 (52)[^a^](#tblfn5){ref-type="table-fn"}                    NR (≥65)                   CKD diagnosis codes                               NSAID prescription in the EMR                                  2007                   8 (8--9)
  Ingrasciotta *et al.* \[[@sfz054-B30]\] (Italy)                      123 primary care physicians meeting standard quality criteria within Ariana database                                                      1989 (51)                                       72 (NR)                    CKD diagnosis codes                               NSAID prescription reimbursed by National Health System      2006--11               56 (54--58)
  Keohane *et al.* \[[@sfz054-B36]\] (Ireland)                         At risk patients[^b^](#tblfn6){ref-type="table-fn"} from primary care 'training practice' (currently 18 practices)       158 (56)[^a^](#tblfn5){ref-type="table-fn"}                      76 (10)                    Single eGFR (MDRD)                                NSAID prescription in EMR                                       NR                    3 (1--5)
  Stage 3: 92%                                                                                                                                                                                                                                                                                                                                                                                                         
  Stage 4: 6%                                                                                                                                                                                                                                                                                                                                                                                                          
  Stage 5: 1%                                                                                                                                                                                                                                                                                                                                                                                                          
  Koffeman *et al.* \[[@sfz054-B28]\] (Netherlands)                    Four primary care practices in the Rotterdam region                                                                       8 (49)[^a^](#tblfn5){ref-type="table-fn"}      69 (10)[^a^](#tblfn5){ref-type="table-fn"}  Single eGFR (NR)                                  Any OTC NSAID use reported via questionnaire                   2012                  25 (0--50)
  Stages 4--5: 100%                                                                                                                                                                                                                                                                                                                                                                                                    
  Martinez-Ramirez *et al.* \[[@sfz054-B33]\] (Mexico)                 Patients without a nephrology referral from two primary care units                                                                         53 (38)                                       62.8 (9.9)                  eGFR (MDRD) and/or micro-/ macroalbuminuria       NSAID use in medical chart                                      NR                  32 (20--45)
  Stage 1: 39% (plus albuminuria)[^c^](#tblfn7){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                   
  Stage 2: 34% (plus albuminuria)[^c^](#tblfn7){ref-type="table-fn"}                                                                                                                                                                                                                                                                                                                                                   
  Stage 3: 27%                                                                                                                                                                                                                                                                                                                                                                                                         

Values are given for whole study population.

Patients with a known renal disorder or impairment, type 1 or 2 diabetes mellitus, hypertension, cardiovascular disease, peripheral vascular disease, hyperlipidemia and structural urological disorders.

All patients within this eGFR stage also had ≥30 mg/day of albuminuria.

SD, standard deviation; MDRD, Modification of Diet in Renal Disease equation; EMR, electronic medical record; NR, not reported; OTC, over the counter.

Study populations varied widely ([Tables 1](#sfz054-T1){ref-type="table"} and [2](#sfz054-T2){ref-type="table"}). The mean age ranged from 47 to 83 years, with all patients \>18 years of age. Four studies selected their patient population based on comorbidity other than CKD (e.g. diabetes, hypertension, musculoskeletal complaints and gout) \[[@sfz054-B26], [@sfz054-B35]\]. Two studies were not specifically based in a primary care practice. One was conducted using claims data from a major New York State insurer and was eligible for inclusion because the authors specifically provided prescription data for patients who had not been seen by a nephrologist and were therefore considered primary care patients \[[@sfz054-B32]\]. The other study was conducted in a nursing home and was included because \>96% of the patients were regularly followed by a primary care physician and a very small proportion were followed by medical specialists \[[@sfz054-B25]\].

CKD and NSAID definitions
-------------------------

The definition of CKD differed substantially across studies. Seven studies required a single low estimated GFR (eGFR) value \[[@sfz054-B25], [@sfz054-B26], [@sfz054-B28], [@sfz054-B33], [@sfz054-B35]\]. Three studies required two separate eGFR values separated by at least 3 months \[[@sfz054-B31], [@sfz054-B32], [@sfz054-B34]\]. Of the studies using eGFR, the severity of CKD among included patients varied widely ([Tables 1](#sfz054-T1){ref-type="table"} and [2](#sfz054-T2){ref-type="table"}) \[[@sfz054-B26], [@sfz054-B28], [@sfz054-B33], [@sfz054-B37]\]. Only one study considered microalbuminuria, allowing for the identification of CKD Stages 1 and 2 \[[@sfz054-B33]\]. Three studies relied on recorded CKD diagnostic and procedure codes without specific staging information \[[@sfz054-B27], [@sfz054-B29], [@sfz054-B30]\].

Nine studies assessed NSAID prescriptions using patients' medical records \[[@sfz054-B25], [@sfz054-B29], [@sfz054-B31], [@sfz054-B33], [@sfz054-B35], [@sfz054-B36]\], of which five specifically excluded low-dose aspirin from reported estimates \[[@sfz054-B27], [@sfz054-B33], [@sfz054-B35], [@sfz054-B36]\]. Two studies reported on prescriptions reimbursed by either a national health provider \[[@sfz054-B30]\] or by private insurance \[[@sfz054-B32]\]. Two studies used patient-administered questionnaires \[[@sfz054-B28], [@sfz054-B34]\] and one used physician-completed study forms \[[@sfz054-B37]\] to assess NSAID use. Only one study provided a list of included NSAIDs \[[@sfz054-B30]\].

Quality assessment
------------------

All the studies had at least a moderate risk of bias ([Supplementary data](#sup1){ref-type="supplementary-material"}, Tables SA3 and SA4). Eleven studies were considered to have a moderate risk of sampling bias and all but one failed to provide age-adjusted prevalences. Two studies were deemed to be at a high risk of bias \[[@sfz054-B28], [@sfz054-B37]\]. The first had a sample size of eight CKD patients and relied on questionnaire data to assess NSAID use, with a 26% response rate \[[@sfz054-B28]\]. Furthermore, patients could be excluded based on their treating physicians' preference and relevant clinical characteristics differed significantly between included and excluded patients. The second study used a random sampling method to identify multiple primary care practitioners but had a \<50% participation rate and provided no comparisons between patients from participating and non-participating practices \[[@sfz054-B37]\].

Prevalence of NSAID use/prescriptions
-------------------------------------

Eleven studies reported exclusively on NSAID prescriptions by primary care physicians, one study evaluated over-the-counter NSAID use \[[@sfz054-B28]\] and two others evaluated a combination of both \[[@sfz054-B25], [@sfz054-B34]\]. The seven studies reporting cross-sectional point prevalences of NSAID use in CKD patients found prevalences between 8% and 21% ([Figure 2](#sfz054-F2){ref-type="fig"}) \[[@sfz054-B25], [@sfz054-B34], [@sfz054-B35], [@sfz054-B37]\]. The remaining seven studies reported period prevalences over follow-up times ranging from 4 weeks \[[@sfz054-B28]\] to 7 years \[[@sfz054-B32]\]. Assuming stable prescription rates, the annual prevalence of NSAID use in CKD patients ranged from 3 to 33% ([Figure 3](#sfz054-F3){ref-type="fig"}) \[[@sfz054-B29], [@sfz054-B33]\]. One study was excluded from this analysis due to very small study size (eight CKD patients, two of which had been prescribed NSAIDs), making the prevalence too unstable for meaningful extrapolation to an annual prevalence value \[[@sfz054-B28]\]. Due to the small number of studies, we were unable to perform a meta-regression analysis to examine the impact of follow-up duration on the overall NSAID prevalence.

![Forest plot of studies assessing point prevalence of NSAID prescription/use among CKD patients in primary care. Weddle (2), retrospective cohort; Weddle (1), prospective cohort; NS, not specified.](sfz054f2){#sfz054-F2}

![Forest plot of studies assessing period prevalence of NSAID prescription/use among CKD patients in primary care, expressed as yearly prevalence. NS, not specified.](sfz054f3){#sfz054-F3}

DISCUSSION
==========

To our knowledge, this is the first systematic review to evaluate physician prescribing or patient use of NSAIDs among CKD patients. We identified 14 studies (13 publications) addressing this question specifically in a primary care setting. Cross-sectional (point) prevalence of NSAID use/prescriptions ranged from 8 to 21% and annual period prevalence ranged from 3 to 33%. These results suggest that despite guidelines recommending against their use, a substantial proportion of CKD patients continue to receive NSAIDs.

Several factors may explain these findings, including lack of awareness of a CKD diagnosis by patients and physicians as well as lack of appreciation of the importance of NSAID avoidance in CKD. Two studies in our review assessing physicians' recognition of CKD status found it to be only 21--24% \[[@sfz054-B31], [@sfz054-B35]\]. While strategies such as automated GFR reporting may be helpful in increasing physicians' identification of CKD patients \[[@sfz054-B38], [@sfz054-B39]\], this may not be the only challenge. In our review, one study assessed the change in NSAID prevalence before and after a physician-documented CKD diagnosis and found only a very small decrease in NSAID prescribing (from 47% to 42%) \[[@sfz054-B30]\]. A much more significant decrease in prescribing prevalence was seen in the year following patient entry into dialysis (30%). Furthermore, another study \[[@sfz054-B31]\] reported only a small decrease (from 24% to 20%) in inappropriate medication prescriptions between CKD patients whose physicians had recognized their diagnosis versus those whose physicians had not, although data for NSAIDs alone were not available.

Only one study evaluated the indication for NSAID prescription and found that the overwhelming majority were prescribed for osteoarticular disease \[[@sfz054-B30]\]. Although alternative therapies exist, NSAIDs may offer superior pain relief in conditions such as arthritis, and our findings may reflect instances where alternatives to NSAIDs have been attempted but were unsuccessful \[[@sfz054-B40]\]. Thus, despite recommendations to avoid NSAIDs in CKD patients, it may be difficult to do so, given the potential beneficial effects of NSAIDs on quality of life and pain relief in such patients. Indications of use and the presence of therapeutic alternatives remain important considerations to be assessed in future studies in this area.

Our study has several potential limitations. There was heterogeneity of the primary care settings of individual studies (e.g. variations in health care organization and practice characteristics). Heterogeneity was also present in the quality of NSAID reporting. Due to the absence of NSAID dose and duration data in most studies, we were unable to present data for chronic NSAID use as we had originally intended \[[@sfz054-B41]\]. The only study to explicitly evaluate chronic NSAID use reported elevated rates, with 36% of CKD patients treated with NSAIDs for periods \>90 days and 17% for \>6 months \[[@sfz054-B30]\]. Lastly, only one study reported NSAID use stratified by sex, showing similar use between men and women ([Supplementary data](#sup1){ref-type="supplementary-material"}, Figure SA1); thus we could not evaluate sex differences in NSAID prescribing in this population, a potential area for future research \[[@sfz054-B30]\].

CONCLUSION
==========

Overall, there are few studies specifically evaluating NSAID prescriptions to CKD patients in the primary care setting despite the widespread use of NSAIDS in the general population and the relatively high prevalence of CKD. More research designed to understand and reduce NSAID prescribing in CKD is warranted. Future studies should use standardized and accepted CKD definitions and should explore the reasons behind persistent NSAID use in patients with CKD to tailor knowledge translation interventions with a goal of reducing NSAID use in this patient population.

SUPPLEMENTARY DATA
==================

[Supplementary data](#sup1){ref-type="supplementary-material"} are available at ckj online.

Supplementary Material
======================

###### 

Click here for additional data file.
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